1. Home
  2. RLMD vs NOTV Comparison

RLMD vs NOTV Comparison

Compare RLMD & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • NOTV
  • Stock Information
  • Founded
  • RLMD 2004
  • NOTV 1974
  • Country
  • RLMD United States
  • NOTV United States
  • Employees
  • RLMD N/A
  • NOTV N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • NOTV Biotechnology: Pharmaceutical Preparations
  • Sector
  • RLMD Health Care
  • NOTV Health Care
  • Exchange
  • RLMD Nasdaq
  • NOTV Nasdaq
  • Market Cap
  • RLMD 53.4M
  • NOTV 57.7M
  • IPO Year
  • RLMD N/A
  • NOTV 1997
  • Fundamental
  • Price
  • RLMD $1.59
  • NOTV $1.41
  • Analyst Decision
  • RLMD Buy
  • NOTV Strong Buy
  • Analyst Count
  • RLMD 3
  • NOTV 1
  • Target Price
  • RLMD $5.00
  • NOTV $5.00
  • AVG Volume (30 Days)
  • RLMD 1.6M
  • NOTV 382.9K
  • Earning Date
  • RLMD 11-06-2025
  • NOTV 08-06-2025
  • Dividend Yield
  • RLMD N/A
  • NOTV N/A
  • EPS Growth
  • RLMD N/A
  • NOTV N/A
  • EPS
  • RLMD N/A
  • NOTV N/A
  • Revenue
  • RLMD N/A
  • NOTV $505,299,000.00
  • Revenue This Year
  • RLMD N/A
  • NOTV $5.64
  • Revenue Next Year
  • RLMD N/A
  • NOTV $5.16
  • P/E Ratio
  • RLMD N/A
  • NOTV N/A
  • Revenue Growth
  • RLMD N/A
  • NOTV 0.85
  • 52 Week Low
  • RLMD $0.24
  • NOTV $1.15
  • 52 Week High
  • RLMD $3.98
  • NOTV $6.48
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 74.57
  • NOTV 34.35
  • Support Level
  • RLMD $1.44
  • NOTV $1.36
  • Resistance Level
  • RLMD $1.72
  • NOTV $1.68
  • Average True Range (ATR)
  • RLMD 0.24
  • NOTV 0.11
  • MACD
  • RLMD 0.05
  • NOTV -0.02
  • Stochastic Oscillator
  • RLMD 86.90
  • NOTV 10.00

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: